Sentinel node localization in cutaneous melanoma: lymphoscintigraphy with colloids and antibody fragments versus blue dye mapping

Abstract. In stage I cutaneous melanoma, biopsy of the first tumour-draining lymph node (sentinel node, SN) may replace routine elective lymph node dissection (ELND). The patent blue dye (PBD) technique has been shown to be an original method for the localization of the SN, but its sensitivity is sometimes unsatisfactory, depending on the basin where the SN is located. We compared three methods to locate the SN: intraoperative PBD mapping, lymphoscintigraphy (LS) with an aspecific tracer (colloid) and LS with a specific tracer (monoclonal antibody, MoAb). Fifty patients with cutaneous melanoma were enrolled in this study. The day before surgery LS was performed following an intradermal injection of 55 MBq technetium-99m-labelled HSA colloidal particles (25 patients: group A) or 220 MBq of 99mTc-F(ab’)2 MoAb 225.28 S (25 patients: group B) around the site of the primary lesion. In group B an equal amount of tracer was injected, as a control, in the contralateral site. Early and delayed images were acquired with a gamma camera and SN(s) marked on the skin. In all 50 patients the PBD technique was also performed immediately before surgery. When a blue node was identified intraoperatively, its radioactivity level was measured with a gamma probe. In the absence of blue coloration, the probe alone was used to detect the SN. Lymphoscintigraphic visualization of SNs was possible in 50/50 patients (100%), a total of 73 SNs (38 in group A and 35 in group B) were found, distributed in 55 basins. Gamma probe detection (GPD) allowed the identification of SNs in 49/50 patients (98%), and 72 SNs in 54 basins were localized. By contrast, using PBD, SNs were stained only in 40/50 patients (50 SNs in 40 basins). A tumour-positive SN was histologically proven in 13 patients (26%). In group B, no increase uptake was observed in the seven positive SNs (6/25 patients) compared with the contralateral uninvolved nodes. In conclusion this study demonstrates that LS combined with GPD is a safe method for detecting SNs and is more sensitive than the PBD technique. The use of MoAb fragments did not show any advantage over the non-specific tracer.

[1]  N. Dubin,et al.  Prognosis of patients with pathologic stage II cutaneous malignant melanoma. , 1985, Annals of surgery.

[2]  N. Cascinelli,et al.  Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. , 1977, The New England journal of medicine.

[3]  G. Lyman,et al.  The identification and mapping of melanoma regional nodal metastases: minimally invasive surgery for the diagnosis of nodal metastases. , 1995, The American surgeon.

[4]  C. Balch The role of elective lymph node dissection in melanoma: rationale, results, and controversies. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J C Briggs,et al.  Cutaneous melanoma. , 1993, Journal of the American Academy of Dermatology.

[6]  W. Bodmer,et al.  TARGETING OF IODINE-123-LABELLED TUMOUR-ASSOCIATED MONOCLONAL ANTIBODIES TO OVARIAN, BREAST, AND GASTROINTESTINAL TUMOURS , 1982, The Lancet.

[7]  K. Sikora,et al.  Localisation of metastatic carcinoma by a radiolabelled monoclonal antibody. , 1983, British Journal of Cancer.

[8]  J. Thompson,et al.  Lymphoscintigraphy in high-risk melanoma of the trunk: predicting draining node groups, defining lymphatic channels and locating the sentinel node. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  E. Kim,et al.  Axillary lymphoscintigraphy by radioimmunodetection of carcinoembryonic antigen in breast cancer. , 1979, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  M. Cremonesi,et al.  Optimization of Axillary Lymphoscintigraphy to Detect the Sentinel Node in Breast Cancer , 1997, Tumori.

[11]  N. Cascinelli,et al.  Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities , 1982, Cancer.

[12]  T. Dasgupta,et al.  PROGNOSIS IN MALIGNANT MELANOMA. , 1964, Surgery.

[13]  J. Eary,et al.  Preliminary studies of monoclonal antibody lymphoscintigraphy in malignant melanoma. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  A. Vaughan,et al.  Improved tumour localisation using indium-111 labelled antibodies. , 1983, British medical journal.

[15]  K. M. Hwang,et al.  Monoclonal antibodies in the lymphatics: selective delivery to lymph node metastases of a solid tumor. , 1983, Science.

[16]  R. MacKie,et al.  Intraoperative lymphatic mapping using patent blue V dye to identify nodal micrometastases in malignant melanoma , 1994 .

[17]  D. Driscoll,et al.  Groin dissection in malignant melanoma. , 1987, The British journal of surgery.

[18]  M. Landthaler,et al.  Benefit of elective lymph node dissection in subgroups of melanoma patients. Results of a multicenter study of 3616 patients , 1993, Cancer.

[19]  C. Balch,et al.  A Comparison of Prognostic Factors and Surgical Results in 1,786 Patients with Localized (Stage I) Melanoma Treated in Alabama, USA, and New South Wales, Australia , 1982, Annals of surgery.

[20]  M. Ross,et al.  The Orderly Progression of Melanoma Nodal Metastases , 1994, Annals of surgery.

[21]  T. K. Gupta Results of treatment of 269 patients with primary cutaneous melanoma: a five-year prospective study. , 1977, Annals of surgery.

[22]  J. Andrews,et al.  IMMUNOSCINTIGRAPHY FOR DETECTION OF LYMPH NODE METASTASES FROM BREAST CANCER , 1984, The Lancet.

[23]  R. Coombes,et al.  LOCATION OF METASTATIC BREAST CARCINOMA BY A MONOCLONAL ANTIBODY CHELATE LABELLED WITH INDIUM-111 , 1983, The Lancet.

[24]  H Franz,et al.  [Monoclonal antibodies in diagnosis and therapy]. , 1989, Die Pharmazie.

[25]  D L Morton,et al.  Technical details of intraoperative lymphatic mapping for early stage melanoma. , 1992, Archives of surgery.

[26]  A. Siccardi,et al.  Improved immunoscintigraphy by subcutaneous injection of 99mTc or 111In labelled F(ab')2 fragments of an anti-melanoma monoclonal antibody. , 1986, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[27]  P. Lam Minimal-access surgery for staging of malignant melanoma , 1996 .

[28]  B. Kroon,et al.  Elective lymph node dissection in melanoma: still a controversial issue. , 1991, The Netherlands journal of surgery.

[29]  F. Sim,et al.  Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. , 1986, Mayo Clinic proceedings.

[30]  A. Luini,et al.  Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node in breast cancer. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.